A new trading day began on Monday, with Moderna Inc (NASDAQ: MRNA) stock price down -2.29% from the previous day of trading, before settling in for the closing price of $33.64. MRNA’s price has ranged from $23.15 to $129.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -42.94% over the past five years. Meanwhile, its annual earnings per share averaged -8.59%. With a float of $342.49 million, this company’s outstanding shares have now reached $387.00 million.
Let’s look at the performance matrix of the company that is accounted for 5800 employees. In terms of profitability, gross margin is 52.55%, operating margin of -118.04%, and the pretax margin is -107.82%.
Moderna Inc (MRNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 11.44%, while institutional ownership is 72.15%. The most recent insider transaction that took place on Jun 11 ’25, was worth 8,736. In this transaction Director of this company sold 312 shares at a rate of $28.00, taking the stock ownership to the 580 shares. Before that another transaction happened on Jun 11 ’25, when Company’s Director proposed sale 312 for $28.00, making the entire transaction worth $8,736.
Moderna Inc (MRNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -8.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.75% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Here are Moderna Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.97 in the next quarter and is forecasted to reach -7.46 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Moderna Inc (NASDAQ: MRNA) saw its 5-day average volume 11.0 million, a negative change from its year-to-date volume of 11.24 million. As of the previous 9 days, the stock’s Stochastic %D was 89.53%.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 64.93%, which indicates a significant decrease from 81.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.50 in the past 14 days, which was lower than the 1.69 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.32, while its 200-day Moving Average is $37.15. Nevertheless, the first resistance level for the watch stands at $33.43 in the near term. At $34.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.50. If the price goes on to break the first support level at $32.37, it is likely to go to the next support level at $31.87. Assuming the price breaks the second support level, the third support level stands at $31.31.
Moderna Inc (NASDAQ: MRNA) Key Stats
With a market capitalization of 12.71 billion, the company has a total of 386,742K Shares Outstanding. Currently, annual sales are 3,236 M while annual income is -3,561 M. The company’s previous quarter sales were 108,000 K while its latest quarter income was -971,000 K.
